



Capnia Announces Presentation of CoSense® and Other Pipeline Candidate Data at the 2016 Pediatric Academic Societies Annual Meeting

April 20, 2016

REDWOOD CITY, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced five posters and one oral presentation relating to scientific data for its CoSense ETCO monitor and other pipeline candidates at the 2016 Pediatric Academic Societies (PAS) Annual Meeting, being held April 30 - May 3, 2016 in Baltimore, MD.

Details for the presentations at PAS are as follows:

Oral Presentation

Title: Point-of-care screening for sickle cell anemia with an end-tidal carbon monoxide monitor

Date and time: Monday, May 2, 2016, 9:15 AM ET

Session room: 344

Session info: Platform 3120—Hematology/Oncology

Poster Presentations

Title: Use of a novel automatic breath test technology for H₂ breath testing in infants and young children

Date: Saturday, April 30, 2016

Location: Exhibit Hall F

Board number: 499

Session info: Poster Session 1511—Gastroenterology/Hepatology/Nutrition (1:00 PM – 4:00 PM)

Title: Identification of hemolysis in the well-baby nursery

Date: Saturday, April 30, 2016

Location: Exhibit Hall F

Board number: 601

Session info: Poster Session 1523—Neonatology: Neonatal Hematology & Bilirubin Metabolism: Diagnosis and Therapy of Hyperbilirubinemia (1:00 PM - 4:00 PM ET)

Title: Pre-discharge management of Hyperbilirubinemia: Identification of Hemolysis

Date: Saturday, April 30, 2016

Location: Exhibit Hall F

Board number: 600

Session info: Poster Session 1523—Neonatology: Neonatal Hematology & Bilirubin Metabolism: Diagnosis and Therapy of Hyperbilirubinemia (1:00 PM - 4:00 PM ET)

Title: Infant birth weight and tidal volume compatibility of the CoSense ETCO monitor

Date: Monday, May 2, 2016

Location: Exhibit Hall F

Board number: 574

Session info: Poster Session 3863—Neonatology: NICU Practices and Procedures II (4:15 PM – 7:30 PM ET)

Title: A new point-of-care breath sensing technology; applicability in neonatology and pediatric medicine

Date: Tuesday, May 3, 2016

Location: Exhibit Hall F

Board number: 590

Session info: Poster Session 4169— Neonatology: Neonatal Potpourri: Nutrition and Renal Topics (7:00 AM - 11:00 AM ET)

About Capnia

Capnia, Inc. is a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs. Capnia's lead commercial product, CoSense, is based on the Sensalyze™ Technology Platform. It is a portable, non-invasive device that rapidly and accurately measures carbon monoxide (CO) in exhaled breath. CoSense has 510(k) clearance for sale in the U.S. and has received CE Mark certification for sale in the European Union. CoSense is used for the monitoring of CO from internal sources (such as hemolysis, a dangerous condition in which red blood cells degrade rapidly), as well as external sources (such as CO poisoning and smoke inhalation). The initial target market is newborns with jaundice that are at risk for hemolysis, comprising approximately three million births in the U.S. and European Union. The Company's commercial, neonatology-focused product line also includes innovative pulmonary resuscitation solutions, including the NeoPIP™ Infant T-Piece Resuscitator and Universal T-Piece Circuit consumables. Capnia's proprietary therapeutic technology uses nasal, non-inhaled CO₂ and is being evaluated to treat the symptoms of allergies, as well as the trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine.

Investor Relations Contact:
Michelle Carroll/Susie Kim
Argot Partners
(212) 600-1902
michelle@argotpartners.com
susan@argotpartners.com

 Primary Logo

Capnia, Inc.